References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30, doi:10.3322/caac.21590.
2. Zappa, C.; Mousa, S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016, 5, 288–300, doi:10.21037/tlcr.2016.06.07.
3. Turnis, M.E.; Andrews, L.P.; Vignali, D.A.A. Inhibitory receptors as targets for cancer immunotherapy. Eur. J. Immunol. 2015, 45, 1892–1905, doi:10.1002/eji.201344413.
4. Wherry, E.J.; Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 2015, 15, 486–499, doi:10.1038/nri3862.
5. Francisco, L.M.; Sage, P.T.; Sharpe, A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 2010, 236, 219–242, doi:10.1111/j.1600-065X.2010.00923.x.
6. Paulsen, E.-E.; Kilvaer, T.K.; Khanehkenari, M.R.; Al-Saad, S.; Hald, S.M.; Andersen, S.; Richardsen, E.; Ness, N.; Busund, L.-T.; Bremnes, R.M.; et al. Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach. Clin. Lung Cancer 2017, 18, 220–233.e8, doi:10.1016/j.cllc.2016.09.009.
7. Poole, R.M. Pembrolizumab: First Global Approval. Drugs 2014, 74, 1973–1981, doi:10.1007/s40265-014-0314-5.
8. Brahmer, J.R.; Hammers, H.; Lipson, E.J. Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015, 11, 1307–1326, doi:10.2217/fon.15.52.
9. Lee, H.T.; Lee, J.Y.; Lim, H.; Lee, S.H.; Moon, Y.J.; Pyo, H.J.; Ryu, S.E.; Shin, W.; Heo, Y.-S. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci. Rep. 2017, 7, 5532, doi:10.1038/s41598-017-06002-8.
10. Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am. J. Clin. Oncol. 2016, 39, 98–106, doi:10.1097/COC.0000000000000239.
11. Genova, C.; Rijavec, E.; Barletta, G.; Sini, C.; Dal Bello, M.G.; Truini, M.; Murolo, C.; Pronzato, P.; Grossi, F. Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin. Biol. Ther. 2012, 12, 939–948, doi:10.1517/14712598.2012.681371.
12. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015, 373, 23–34, doi:10.1056/NEJMoa1504030.
13. Wei, S.C.; Anang, N.-A.A.S.; Sharma, R.; Andrews, M.C.; Reuben, A.; Levine, J.H.; Cogdill, A.P.; Mancuso, J.J.; Wargo, J.A.; Pe’er, D.; et al. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl. Acad. Sci. USA 2019, 116, 22699–22709, doi:10.1073/pnas.1821218116.
14. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448, 561–566, doi:10.1038/nature05945.
15. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.-H.; Li, D.; Capelletti, M.; Cortot, A.B.; Chirieac, L.; Iacob, R.E.; Padera, R.; et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070–1074, doi:10.1038/nature08622.
16. Choi, Y.L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.; et al. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. N. Engl. J. Med. 2010, 363, 1734–1739, doi:10.1056/NEJMoa1007478.
17. Camidge, D.R.; Kim, H.R.; Ahn, M.-J.; Yang, J.C.-H.; Han, J.-Y.; Lee, J.-S.; Hochmair, M.J.; Li, J.Y.-C.; Chang, G.-C.; Lee, K.H.; et al. Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 379, 2027–2039, doi:10.1056/NEJMoa1810171.
18. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. N. Engl. J. Med. 2010, 362, 2380–2388, doi:10.1056/NEJMoa0909530.
19. Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 378, 113–125, doi:10.1056/NEJMoa1713137.
20. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252–264, doi:10.1038/nrc3239.
21. Bristol Myers Squibb. OPDIVO™ (Nivolumab) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s083lbl.pdf (accessed on 9 May 2020).
22. Carbone, D.P.; Reck, M.; Paz-Ares, L.; Creelan, B.; Horn, L.; Steins, M.; Felip, E.; van den Heuvel, M.M.; Ciuleanu, T.E.; Badin, F.; et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 376, 2415–2426, doi:10.1056/NEJMoa1613493.
23. Kobayashi, T.; Iwama, S.; Yasuda, Y.; Okada, N.; Tsunekawa, T.; Onoue, T.; Takagi, H.; Hagiwara, D.; Ito, Y.; Morishita, Y. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study. J. Endocr. Soc. 2018, 2, 241–251.
24. Yamauchi, I.; Sakane, Y.; Fukuda, Y.; Fujii, T.; Taura, D.; Hirata, M.; Hirota, K.; Ueda, Y.; Kanai, Y.; Yamashita, Y. Clinical features of nivolumab-induced thyroiditis: A case series study. Thyroid 2017, 27, 894–901.
25. Jotatsu, T.; Oda, K.; Yamaguchi, Y.; Noguchi, S.; Kawanami, T.; Kido, T.; Satoh, M.; Yatera, K. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. Immunotherapy 2018, 10, 85–91.
26. Dudzińska, M.; Szczyrek, M.; Wojas-Krawczyk, K.; Świrska, J.; Chmielewska, I.; Zwolak, A. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review. Cancers 2020, 12, 2314.
27. Yoshino, K.; Nakayama, T.; Ito, A.; Sato, E.; Kitano, S. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: Two case reports. BMC Cancer 2019, 19, 1019.
28. Mathew Thomas, V.; Bindal, P.; Ann Alexander, S.; McDonald, K. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. J. Oncol. Pharm. Pract. 2020, 26, 459–461.
29. Vandiver, J.W.; Singer, Z.; Harshberger, C. Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Target. Oncol. 2016, 11, 553–556.
30. Merck Sharp & Dohme Corp. KEYTRUDA® (Pembrolizumab) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s084lbl.pdf (accessed on 9 June 2020).
31. Mok, T.S.K.; Wu, Y.L.; Kudaba, I.; Kowalski, D.M.; Cho, B.C.; Turna, H.Z.; Castro, G., Jr.; Srimuninnimit, V.; Laktionov, K.K.; Bondarenko, I.; et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet Lond. Engl. 2019, 393, 1819–1830, doi:10.1016/s0140-6736(18)32409-7.
32. Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2019, 37, 537–546, doi:10.1200/jco.18.00149.
33. Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833, doi:10.1056/NEJMoa1606774.
34. Leroy, V.; Templier, C.; Faivre, J.-B.; Scherpereel, A.; Fournier, C.; Mortier, L.; Wemeau-Stervinou, L. Pembrolizumab-induced pneumonitis. ERJ Open Res. 2017, 3, 00081-2016.
35. Zhou, C.; Klionsky, Y.; Treasure, M.E.; Bruno, D.S. Pembrolizumab-induced immune-mediated colitis in a patient with concurrent Clostridium difficile infection. Case Rep. Oncol. 2019, 12, 164–170.
36. Ahmed, M.; Francis, G. Pembrolizumab-Induced Microscopic Colitis. Am. J. Gastroenterol. 2018, 113, 629–630.
37. Aivazian, K.; Long, G.V.; Sinclair, E.C.; Kench, J.G.; McKenzie, C.A. Histopathology of pembrolizumab-induced hepatitis: A case report. Pathology 2017, 49, 789–792.
38. Kobayashi, K.; Nakachi, I.; Mitsuishi, A.; Arai, D.; Sakurai, K.; Masaki, K.; Chiyotani, A.; Takahashi, H.; Tahara, T.; Soejima, K. Successful Retreatment Using Pembrolizumab for Non-small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report. Clin. Lung Cancer 2020, 21, e30.
39. Kawaji, L.D.R.; Villanueva, M.G.M.; Villa, M.L. SUN-276 Pembrolizumab-Induced Secondary Adrenal Insufficiency Presenting as Severe Hyponatremia in an 80-Year-Old Male. J. Endocr. Soc. 2020, 4, SUN–276.
40. Oristrell, G.; Bañeras, J.; Ros, J.; Muñoz, E. Cardiac tamponade and adrenal insufficiency due to pembrolizumab: A case report. Eur. Heart J. Case Rep. 2018, 2, yty038.
41. Imblum, B.A.; Baloch, Z.W.; Fraker, D.; LiVolsi, V.A. Pembrolizumab-induced thyroiditis. Endocr. Pathol. 2019, 30, 163–167.
42. Matsuoka, N.; Tsuji, K.; Ichihara, E.; Hara, T.; Fukushima, K.; Toma, K.; Kitamura, S.; Inagaki, K.; Sugiyama, H.; Wada, J. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: A case report. BMC Nephrol. 2020, 21, 1–5.
43. Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 372, 2018–2028, doi:10.1056/NEJMoa1501824.
44. Maamari, J.; Yeung, S.-C.J.; Chaftari, P.S. Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am. J. Emerg. Med. 2019, 37, 376.e1–376.e2.
45. Chae, Y.K.; Chiec, L.; Mohindra, N.; Gentzler, R.; Patel, J.; Giles, F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol. Immunother. 2017, 66, 25–32.
46. Shirali, A.C.; Perazella, M.A.; Gettinger, S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. Am. J. Kidney Dis. 2016, 68, 287–291, doi:10.1053/j.ajkd.2016.02.057.
47. Taki, T.; Oda, N.; Fujioka, Y.; Mitani, R.; Tokura, T.; Takata, I.; Oshiro, Y.; Takigawa, N. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab following Tubulointerstitial Nephritis due to Pembrolizumab. Intern. Med. 2020, 29, 1639–1642.
48. Genentech Inc. TECENTRIQ® (Atezolizumab) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf (accessed on 9 June 2020).
49. Li, J.; Deng, X.; Wang, B.; Li, W. Fatal outcome of atezolizumab in a patient with immune-mediated pneumonitis, thrombocytopenia, and cardiac dysfunction: A case report. Int. J. Clin. Pharmacol. Ther. 2019, 57, 607–611.
50. Hsu, P.-C.; Li, S.-H.; Yang, C.-T. Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis. J. Thorac. Oncol. 2018, 13, e227–e230.
51. Ikeda, S.; Kato, T.; Kenmotsu, H.; Ogura, T.; Iwasawa, S.; Sato, Y.; Harada, T.; Kubota, K.; Tokito, T.; Okamoto, I. A phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias. J. Thorac. Oncol. 2020, doi:10.1016/j.jtho.2020.08.018.
52. Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016, 387, 1837–1846, doi:10.1016/S0140-6736(16)00587-0.
53. Schmid, P.; Rugo, H.S.; Adams, S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Henschel, V.; Molinero, L.; Chui, S.Y.; et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020, 21, 44–59, doi:10.1016/S1470-2045(19)30689-8.
54. Kanie, K.; Iguchi, G.; Bando, H.; Fujita, Y.; Odake, Y.; Yoshida, K.; Matsumoto, R.; Fukuoka, H.; Ogawa, W.; Takahashi, Y. Two cases of atezolizumab-induced hypophysitis. J. Endocr. Soc. 2018, 2, 91–95.
55. Socinski, M.A.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New Engl. J. Med. 2018, 378, 2288–2301, doi:10.1056/NEJMoa1716948.
56. West, H.; McCleod, M.; Hussein, M.; Morabito, A.; Rittmeyer, A.; Conter, H.J.; Kopp, H.-G.; Daniel, D.; McCune, S.; Mekhail, T.; et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019, 20, 924–937, doi:10.1016/S1470-2045(19)30167-6.
57. Reuben, A.; Petaccia de Macedo, M.; McQuade, J.; Joon, A.; Ren, Z.; Calderone, T.; Conner, B.; Wani, K.; Cooper, Z.A.; Tawbi, H. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 2017, 6, e1361097.
58. BRISTOL MYERS SQUIBB. YERVOY® (Ipilimumab) [Packzage Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s111lbl.pdf (accessed on 9 June 2020).
59. Lai, K.; Shannon, V.; Bashoura, L.; Faiz, S. Ipilimumab Pneumonitis Treated with Infliximab. In A39. Drug Related Case Reports; American Thoracic Society: New York, NY, USA, 2019; p. A1505.
60. Witges, K.; Shafer, L.A.; Zarychanski, R.; Abou-Setta, A.M.; Rabbani, R.; Dingwall, O.; Bernstein, C.N. Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis. Drug Saf. 2020, 1–12, doi:10.1007/s40264-020-00979-4
61. Pagès, C.; Gornet, J.M.; Monsel, G.; Allez, M.; Bertheau, P.; Bagot, M.; Lebbé, C.; Viguier, M. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013, 23, 227–230.
62. Izzedine, H.; Gueutin, V.; Gharbi, C.; Mateus, C.; Robert, C.; Routier, E.; Thomas, M.; Baumelou, A.; Rouvier, P. Kidney injuries related to ipilimumab. Investig. New Drugs 2014, 32, 769–773.
63. Kidd, J.M.; Gizaw, A.B. Ipilimumab-associated minimal-change disease. Kidney Int. 2016, 89, 720.
64. Thajudeen, B.; Madhrira, M.; Bracamonte, E.; Cranmer, L.D. Ipilimumab granulomatous interstitial nephritis. Am. J. Ther. 2015, 22, e84–e87.
65. Fadel, F.; Karoui, K.E.; Knebelmann, B. Anti-CTLA4 antibody–induced lupus nephritis. N. Engl. J. Med. 2009, 361, 211–212.
66. Ferrari, S.M.; Fallahi, P.; Galetta, F.; Citi, E.; Benvenga, S.; Antonelli, A. Thyroid disorders induced by checkpoint inhibitors. Rev. Endocr. Metab. Disord. 2018, 19, 325–333.
67. Gaballa, S.; Hlaing, K.M.; Mahler, N.; Moursy, S.; Ahmed, A. A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary. Cureus 2020, 12, e8602.
68. Shiba, M.; Inaba, H.; Ariyasu, H.; Kawai, S.; Inagaki, Y.; Matsuno, S.; Iwakura, H.; Yamamoto, Y.; Nishi, M.; Akamizu, T. Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody. Intern. Med. 2018, 57, 2029–2034.
69. Tsiogka, A.; Jansky, G.L.; Bauer, J.W.; Koelblinger, P. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res. 2017, 27, 524–525.
70. AstraZeneca Pharmaceuticals LP. IMFINZI® (Durvalumab) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761069s020lbl.pdf (accessed on 9 July 2020).
71. Garassino, M.C.; Cho, B.-C.; Kim, J.-H.; Mazières, J.; Vansteenkiste, J.; Lena, H.; Corral Jaime, J.; Gray, J.E.; Powderly, J.; Chouaid, C.; et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study. Lancet Oncol. 2018, 19, 521–536, doi:10.1016/S1470-2045(18)30144-X.
72. Tonk, E.H.J.; van Lindert, A.S.R.; Verhoeff, J.J.C.; Suijkerbuijk, K.P.M. Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab. Case Rep. Oncol. 2019, 12, 621–624, doi:10.1159/000502202.
73. Nakamura, M.; Otsuka, T.; Hayashi, R.; Horita, T.; Ota, M.; Sakurai, N.; Takano, H.; Hayashi, T.; Kumagai, M.; Yamada, S. Durvalumab-Induced Immune-Related Hepatitis in a Patient with Non-small Cell Lung Cancer. Intern. Med. 2020, 4699-4620.
74. Yang, H.; Shen, K.; Zhu, C.; Li, Q.; Zhao, Y.; Ma, X. Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. Drug Des. Dev. Ther. 2018, 12, 2085.
75. Coleman, E.; Ko, C.; Dai, F.; Tomayko, M.M.; Kluger, H.; Leventhal, J.S. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J. Am. Acad. Dermatol. 2019, 80, 990–997, doi:10.1016/j.jaad.2018.10.062.
76. Lin, W.-H.; Lee, K.-Y.; Lee, W.-R.; Shih, Y.-H. Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment. J. Dermatol. 2020, 47, 1041–1045, doi:10.1111/1346-8138.15371.
77. Gorantla, Y.; Amblee, A.; Lee, Y.L.; Yap, S.E.T. SAT-506 Rare Case of Durvalumab-Induced Thyroiditis, Transient Secondary Adrenal Insufficiency and Autoimmune Diabetes. J. Endocr. Soc. 2020, 4, SAT–506.
78. Mengíbar, J.L.; Capel, I.; Bonfill, T.; Mazarico, I.; Espuña, L.C.; Caixàs, A.; Rigla, M. Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment. Endocrinol. Diabetes Metab. Case Rep. 2019, 2019, doi:10.1530/EDM-19-0045.
79. Patel, S.; Chin, V.; Greenfield, J.R. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. Endocrinol. Diabetes Metab. Case Rep. 2019, 2019, 98.
80. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2002, 346, 92–98, doi:10.1056/NEJMoa011954.
81. Scagliotti, G.V.; Parikh, P.; von Pawel, J.; Biesma, B.; Vansteenkiste, J.; Manegold, C.; Serwatowski, P.; Gatzemeier, U.; Digumarti, R.; Zukin, M.; et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26, 3543–3551, doi:10.1200/jco.2007.15.0375.
82. Ozkok, A.; Edelstein, C.L. Pathophysiology of cisplatin-induced acute kidney injury. Biomed. Res. Int. 2014, 2014, 967826, doi:10.1155/2014/967826.
83. Rowinsky, E.K.; Donehower, R.C. Paclitaxel (Taxol). N. Engl. J. Med. 1995, 332, 1004–1014, doi:10.1056/nejm199504133321507.
84. Verweij, J.; Clavel, M.; Chevalier, B. Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann. Oncol. Off. J. Eur. Soc. Med Oncol. 1994, 5, 495–505, doi:10.1093/oxfordjournals.annonc.a058903.
85. Vu, T.; Ellard, S.; Speers, C.H.; Taylor, S.C.M.; de Lemos, M.L.; Hu, F.; Kuik, K.; Olivotto, I.A. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: A population-based evaluation. Ann. Oncol. 2008, 19, 461–464, doi:10.1093/annonc/mdm527.
86. Jones, S.E.; Erban, J.; Overmoyer, B.; Budd, G.T.; Hutchins, L.; Lower, E.; Laufman, L.; Sundaram, S.; Urba, W.J.; Pritchard, K.I.; et al. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer. J. Clin. Oncol. 2005, 23, 5542–5551, doi:10.1200/jco.2005.02.027.
87. Scotté, F.; Tourani, J.-M.; Banu, E.; Peyromaure, M.; Levy, E.; Marsan, S.; Magherini, E.; Fabre-Guillevin, E.; Andrieu, J.-M.; Oudard, S. Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand. J. Clin. Oncol. 2005, 23, 4424–4429, doi:10.1200/jco.2005.15.651.
88. Martín, M.; Seguí, M.A.; Antón, A.; Ruiz, A.; Ramos, M.; Adrover, E.; Aranda, I.; Rodríguez-Lescure, A.; Große, R.; Calvo, L.; et al. Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. N. Engl. J. Med. 2010, 363, 2200–2210, doi:10.1056/NEJMoa0910320.
89. Lee, H.; Park, S.; Kang, J.E.; Lee, H.M.; Kim, S.A.; Rhie, S.J. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis. Sci. Rep. 2020, 10, 530, doi:10.1038/s41598-019-57380-0.
90. Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Hegg, R.; Im, S.-A.; Shaw Wright, G.; et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 2018, 379, 2108–2121, doi:10.1056/NEJMoa1809615.
91. Eli, L. GEMZAR (Gemcitabine) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf (accessed on 9 October 2020).
92. Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.-L.; Gourgou-Bourgade, S.; de la Fouchardière, C.; et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N. Engl. J. Med. 2011, 364, 1817–1825, doi:10.1056/NEJMoa1011923.
93. Sabria-Trias, J.; Bonnaud, F.; Sioniac, M. Severe interstitial pneumonitis related to gemcitabine. Rev. Des Mal. Respir. 2002, 19, 645–647.
94. Pavlakis, N.; Bell, D.R.; Millward, M.J.; Levi, J.A. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer Interdiscip. Int. J. Am. Cancer Soc. 1997, 80, 286–291.
95. De Pas, T.; Curigliano, G.; Franceschelli, L.; Catania, C.; Spaggiari, L.; De Braud, F. Gemcitabine-induced systemic capillary leak syndrome. Ann. Oncol. 2001, 12, 1651–1652.
96. Pulkkanen, K.; Kataja, V.; Johansson, R. Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: A case report. J. Chemother. 2003, 15, 287–289.
97. Els, N.J.V.; Miller, V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998, 114, 1779–1781.
98. Russell, M.T.; Nassif, A.S.; Cacayorin, E.D.; Awwad, E.; Perman, W.; Dunphy, F. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn. Reson. Imaging 2001, 19, 129–132.
99. Kwon, E.J.; Kim, S.W.; Kim, K.K.; Seo, H.S.; Kim, D.Y. A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2009, 41, 53.
100. Lilly USA LLC. ALIMTA (Pemetrexed) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021462s053lbl.pdf (accessed on 13 September 2020).
101. Huang, J.-J.; Ma, S.-X.; Hou, X.; Wang, Z.; Zeng, Y.-D.; Qin, T.; Dinglin, X.-X.; Chen, L.-K. Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. Chin. J. Cancer 2015, 34, 94–98.
102. Scheinpflug, K.; Menzel, C.; Koch, A.; Kahl, C.; Achenbach, H.J. Toxic epidermal necrolysis related to cisplatin and pemetrexed for metastatic non-small cell lung cancer. Oncol. Res. Treat. 2012, 35, 600–603.
103. Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Çay Şenler, F.; Csőszi, T.; Fülöp, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 379, 2040–2051, doi:10.1056/NEJMoa1810865.
104. Gadgeel, S.; Rodríguez-Abreu, D.; Speranza, G.; Esteban, E.; Felip, E.; Dómine, M.; Hui, R.; Hochmair, M.J.; Clingan, P.; Powell, S.F.; et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020, 38, 1505–1517, doi:10.1200/jco.19.03136.
105. Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 2078–2092, doi:10.1056/NEJMoa1801005.
106. Jassem, J.; Herbst, R.S.; de Marinis, F.; Cadranel, J.; Csőszi, T.; Isla, D.; Chen, G.; Syrigos, K.N.; Cortinovis, D.; Hida, T. IMpower110: Clinical Safety in a Phase III Study of Atezolizumab (Atezo) Monotherapy (Mono) vs Platinum-Based Chemotherapy (Chemo) in First-Line Non-Small Cell Lung Cancer (NSCLC); American Society of Clinical Oncology: Alexandria, VA, USA, 2020.
107. Administration, U.S.F.D. FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression (accessed on 31 May 2020).
108. Herbst, R.S.; Giaccone, G.; de Marinis, F.; Reinmuth, N.; Vergnenegre, A.; Barrios, C.H.; Morise, M.; Felip, E.; Andric, Z.; Geater, S.; et al. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. N. Engl. J. Med. 2020, 383, 1328–1339, doi:10.1056/NEJMoa1917346.
109. Reck, M.; Mok, T.S.K.; Nishio, M.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet. Respir. Med. 2019, 7, 387–401, doi:10.1016/s2213-2600(19)30084-0.
110. Reck, M.; Wehler, T.; Orlandi, F.; Nogami, N.; Barone, C.; Moro-Sibilot, D.; Shtivelband, M.; González Larriba, J.L.; Rothenstein, J.; Früh, M.; et al. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020, doi:10.1200/jco.19.03158.
111. Hellmann, M.D.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S.-W.; Carcereny Costa, E.; Park, K.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; et al. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2019, 381, 2020–2031, doi:10.1056/NEJMoa1910231.
112. Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P.F.; et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017, 377, 1345–1356, doi:10.1056/NEJMoa1709684.
113. Reck, M.; Ciuleanu, T.-E.; Dols, M.C.; Schenker, M.; Zurawski, B.; Menezes, J.; Richardet, E.; Bennouna, J.; Felip, E.; Juan-Vidal, O. Nivolumab (NIVO)+ Ipilimumab (IPI)+ 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs 4 Cycles Chemo as First-Line (1L) Treatment (tx) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA; American Society of Clinical Oncology: Alexandria, VA, USA, 2020.
114. Howlader, N.; Forjaz, G.; Mooradian, M.J.; Meza, R.; Kong, C.Y.; Cronin, K.A.; Mariotto, A.B.; Lowy, D.R.; Feuer, E.J. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N. Engl. J. Med. 2020, 383, 640–649, doi:10.1056/NEJMoa1916623.
115. Reck, M.; Kerr, K.M.; Grohé, C.; Manegold, C.; Pavlakis, N.; Paz-Ares, L.; Huber, R.M.; Popat, S.; Thatcher, N.; Park, K.; et al. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: A separate disease entity? Future Oncol. Lond. Engl. 2019, 15, 1363–1383, doi:10.2217/fon-2018-0948.
116. Seliger, B. Basis of PD1/PD-L1 Therapies. J. Clin. Med. 2019, 8, 2168, doi:10.3390/jcm8122168.
117. Alvarez-Argote, J.; Dasanu, C.A. Durvalumab in cancer medicine: a comprehensive review. Expert Opin. Biol. Ther. 2019, 19, 927–935
118. Picardo, S.L.; Doi, J.; Hansen, A.R. Structure and Optimization of Checkpoint Inhibitors. Cancers 2020, 12, 38.